[go: up one dir, main page]

MX2020002645A - Pridopidina para el tratamiento de las discinesias inducidas por fármacos. - Google Patents

Pridopidina para el tratamiento de las discinesias inducidas por fármacos.

Info

Publication number
MX2020002645A
MX2020002645A MX2020002645A MX2020002645A MX2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A
Authority
MX
Mexico
Prior art keywords
drug
subject
induced dyskinesia
pridopidine
treatment
Prior art date
Application number
MX2020002645A
Other languages
English (en)
Other versions
MX383462B (es
Inventor
Aric Orbach
Michal Geva
Michael Hayden
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2020002645A publication Critical patent/MX2020002645A/es
Publication of MX383462B publication Critical patent/MX383462B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona un método para tratar a un sujeto que padece un trastorno del movimiento inducido por fármacos que incluye discinesia inducida por levodopa, que comprende administrar periódicamente al sujeto en necesidad del mismo una cantidad de pridopidina efectiva para tratar al sujeto. La invención proporciona además un método para tratar a un sujeto con riesgo de desarrollar un trastorno del movimiento inducido por fármacos, que incluye discinesia inducida por levodopa. La invención también proporciona composiciones farmacéuticas adecuadas para llevar a cabo estos métodos y envases que contienen dichas composiciones farmacéuticas.
MX2020002645A 2017-09-08 2018-08-30 Pridopidina para el tratamiento de las discinesias inducidas por fármacos MX383462B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US201862649184P 2018-03-28 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
MX2020002645A true MX2020002645A (es) 2021-06-10
MX383462B MX383462B (es) 2025-03-14

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002645A MX383462B (es) 2017-09-08 2018-08-30 Pridopidina para el tratamiento de las discinesias inducidas por fármacos

Country Status (10)

Country Link
US (2) US20190231768A1 (es)
EP (1) EP3678664A1 (es)
JP (1) JP2020533296A (es)
CN (1) CN111343982A (es)
AU (1) AU2018329628B2 (es)
BR (1) BR112020004622A2 (es)
CA (1) CA3075020C (es)
IL (1) IL273044A (es)
MX (1) MX383462B (es)
WO (1) WO2019050775A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
KR20250021199A (ko) 2023-08-03 2025-02-12 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CN101056854B (zh) 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
CN101765428A (zh) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 多巴胺稳定剂的用途
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130216856A1 (en) 2010-07-02 2013-08-22 Marco Burtchen Mechanical component and method of surface hardening
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2013034622A1 (en) 2011-09-07 2013-03-14 Neurosearch A/S Polymorphic form of pridopidine hydrochloride
UY34503A (es) * 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
PE20170302A1 (es) 2013-06-21 2017-03-31 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
JP6526695B6 (ja) 2014-03-10 2019-06-26 アプライド マテリアルズ インコーポレイテッドＡｐｐｌｉｅｄ Ｍａｔｅｒｉａｌｓ，Ｉｎｃｏｒｐｏｒａｔｅｄ 多重荷電粒子ビームリソグラフィのためのピクセルブレンディング
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3261721B1 (en) 2015-02-25 2022-09-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve memory
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
HUE066769T2 (hu) 2016-02-24 2024-09-28 Prilenia Neurotherapeutics Ltd Neurodegeneratív szembetegség kezelése pridopidinnal
CN115671103A (zh) 2016-08-24 2023-02-03 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
BR112019015000A2 (pt) 2017-01-20 2020-04-07 Agency Science Tech & Res uso de pridopidina para o tratamento da síndrome do x frágil
CA3072882C (en) 2017-08-14 2023-03-21 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
WO2019046568A1 (en) * 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Also Published As

Publication number Publication date
US20190231768A1 (en) 2019-08-01
CN111343982A (zh) 2020-06-26
AU2018329628B2 (en) 2021-04-22
CA3075020A1 (en) 2019-03-14
US20190350914A1 (en) 2019-11-21
MX383462B (es) 2025-03-14
WO2019050775A1 (en) 2019-03-14
JP2020533296A (ja) 2020-11-19
AU2018329628A1 (en) 2020-04-16
EP3678664A1 (en) 2020-07-15
US11000519B2 (en) 2021-05-11
BR112020004622A2 (pt) 2020-09-24
CA3075020C (en) 2021-12-07
IL273044A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2020002645A (es) Pridopidina para el tratamiento de las discinesias inducidas por fármacos.
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
CY1125423T1 (el) Μεθοδος in vitro διαφοροποιησης των μεσεγκεφαλικων ντοπαμινεργικων(mda)νευρωνων
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2023000251A (es) Composiciones para usarse en el tratamiento de un trastorno asociado a gen de proproteina convertasa subtilisina kexina (pcsk9).
BR112018003984A2 (pt) anticorpos
MX391815B (es) AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR).
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
PH12018500578A1 (en) Methods of treating inflammatory diseases
AR101740A1 (es) Terapia de combinación y composiciones
MX376200B (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112019023948A2 (pt) tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
CO2021008187A2 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
BR112019000635A2 (pt) inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.